Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRUS Stock Forecast 2025-2026
$40.90
Current Price
$2.83B
Market Cap
Buy 17
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MRUS Price Targets
+168.9%
To High Target of $110.00
+112.7%
To Median Target of $87.00
+44.3%
To Low Target of $59.00
MRUS Price Momentum
-7.4%
1 Week Change
-2.5%
1 Month Change
-8.1%
1 Year Change
-2.7%
Year-to-Date Change
-33.6%
From 52W High of $61.61
+23.2%
From 52W Low of $33.19
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Merus (MRUS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MRUS and similar high-potential opportunities.
Latest MRUS Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, MRUS has a bullish consensus with a median price target of $87.00 (ranging from $59.00 to $110.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $40.90, the median forecast implies a 112.7% upside. This outlook is supported by 17 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRUS Analyst Ratings
17
Buy
0
Hold
0
Sell
MRUS Price Target Range
Low
$59.00
Average
$87.00
High
$110.00
Current: $40.90
Latest MRUS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRUS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $89.00 |
| Apr 9, 2025 | Needham | Ami Fadia | Buy | Reiterates | $83.00 |
| Mar 28, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $109.00 |
| Mar 18, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $109.00 |
| Mar 10, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $70.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $85.00 |
| Feb 28, 2025 | Needham | Ami Fadia | Buy | Maintains | $83.00 |
| Feb 13, 2025 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $84.00 |
| Feb 12, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $0.00 |
| Dec 10, 2024 | Citigroup | Buy | Maintains | $0.00 | |
| Dec 9, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $97.00 |
| Dec 9, 2024 | Needham | Ami Fadia | Buy | Reiterates | $85.00 |
| Dec 5, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $85.00 |
| Dec 5, 2024 | Guggenheim | Michael Schmidt | Buy | Maintains | $111.00 |
| Dec 5, 2024 | Needham | Ami Fadia | Buy | Reiterates | $85.00 |
| Dec 3, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $109.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $85.00 |
| Dec 2, 2024 | Needham | Ami Fadia | Buy | Reiterates | $85.00 |
| Nov 21, 2024 | Goldman Sachs | Richard Law | Buy | Initiates | $73.00 |
| Nov 20, 2024 | Needham | Ami Fadia | Buy | Reiterates | $85.00 |
Merus N.V. (MRUS) Competitors
The following stocks are similar to Merus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Merus N.V. (MRUS) Financial Data
Merus N.V. has a market capitalization of $2.83B with a P/E ratio of 0.0x. The company generates $36.13M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +2.2% quarter-over-quarter, while maintaining an operating margin of -969.9% and return on equity of -42.9%.
Valuation Metrics
Market Cap
$2.83B
Enterprise Value
$2.43B
P/E Ratio
0.0x
PEG Ratio
-10.5x
Price/Sales
78.3x
Growth & Margins
Revenue Growth (YoY)
+2.2%
Gross Margin
N/A
Operating Margin
-969.9%
Net Margin
0.0%
EPS Growth
+2.2%
Financial Health
Cash/Price Ratio
+19.0%
Current Ratio
6.5x
Debt/Equity
1.5x
ROE
-42.9%
ROA
-27.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Merus N.V. (MRUS) Business Model
About Merus N.V.
What They Do
Develops innovative cancer therapies using bispecific antibodies.
Business Model
Merus N.V. operates as a clinical-stage biopharmaceutical company that generates revenue through the development and commercialization of bispecific antibody therapeutics for cancer treatment. Its proprietary Biclonics® technology platform allows the company to create therapies that target multiple malignancy sources simultaneously, enhancing treatment efficacy. The company engages in strategic collaborations and clinical trials to advance its drug pipeline, aiming to bring its innovative cancer therapies to market.
Additional Information
Based in the Netherlands, Merus N.V. is committed to addressing the significant medical need for effective cancer therapies. Its focus on immuno-oncology positions it as a vital player in the biotechnology sector, with ongoing efforts to redefine cancer treatment modalities through groundbreaking research and development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
260
CEO
Dr. Sven Ante Lundberg M.D.
Country
Netherlands
IPO Year
2016
Website
www.merus.nlMerus N.V. (MRUS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -20.69% and 238.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Merus N.V. announced developments in Utrecht, Netherlands, and Cambridge, Massachusetts, on May 8, 2025. Further details were not provided in the excerpt.
Why It Matters
Merus N.V.'s announcement may indicate developments in biotech or pharmaceuticals, affecting stock performance and market sentiment in those sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
3 days ago
Quick Summary
Petosemtamab and pembrolizumab are being tested together in a Phase 2 trial for 1L PD-L1+ r/m HNSCC, with clinical data expected at the 2025 ASCO Annual Meeting.
Why It Matters
The ongoing trial for Petosemtamab combined with pembrolizumab in cancer treatment could impact market sentiment and stock prices of involved biotech firms based on future clinical outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Merus (MRUS) is not expected to have the necessary elements for a potential earnings beat in its upcoming report.
Why It Matters
Merus (MRUS) may underperform in its upcoming earnings report, signaling potential stock weakness and affecting investor sentiment and valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Merus N.V. (MRUS) reported a quarterly loss of $1.40 per share, exceeding the Zacks Consensus Estimate of a $1.16 loss, and up from a $0.59 loss per share a year earlier.
Why It Matters
Merus N.V.'s larger-than-expected quarterly loss raises concerns about financial performance, potentially affecting stock valuation and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Petosemtamab, combined with pembrolizumab, has interim clinical data selected for a poster presentation in first-line PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
Why It Matters
The presentation of positive interim data for Petosemtamab combined with pembrolizumab in a key cancer treatment could indicate potential market advantages and affect stock valuations for involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Merus: Riding The Bispecific Wave In Oncology
1 month ago
Quick Summary
Merus's innovative Biclonics and Multiclonics platforms focus on bispecific antibodies like petosemtamab, which has FDA Breakthrough Therapy designations. The company has a $724M cash runway through 2028.
Why It Matters
Merus's innovative platforms and strong cash position enable strategic growth. FDA Breakthrough designations for petosemtamab highlight its potential, boosting investor confidence in future returns.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About MRUS Stock
What is Merus N.V.'s (MRUS) stock forecast for 2025?
Based on our analysis of 21 Wall Street analysts, Merus N.V. (MRUS) has a median price target of $87.00. The highest price target is $110.00 and the lowest is $59.00.
Is MRUS stock a good investment in 2025?
According to current analyst ratings, MRUS has 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $40.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRUS stock?
Wall Street analysts predict MRUS stock could reach $87.00 in the next 12 months. This represents a 112.7% increase from the current price of $40.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Merus N.V.'s business model?
Merus N.V. operates as a clinical-stage biopharmaceutical company that generates revenue through the development and commercialization of bispecific antibody therapeutics for cancer treatment. Its proprietary Biclonics® technology platform allows the company to create therapies that target multiple malignancy sources simultaneously, enhancing treatment efficacy. The company engages in strategic collaborations and clinical trials to advance its drug pipeline, aiming to bring its innovative cancer therapies to market.
What is the highest forecasted price for MRUS Merus N.V.?
The highest price target for MRUS is $110.00 from at , which represents a 168.9% increase from the current price of $40.90.
What is the lowest forecasted price for MRUS Merus N.V.?
The lowest price target for MRUS is $59.00 from at , which represents a 44.3% increase from the current price of $40.90.
What is the overall MRUS consensus from analysts for Merus N.V.?
The overall analyst consensus for MRUS is bullish. Out of 21 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $87.00.
How accurate are MRUS stock price projections?
Stock price projections, including those for Merus N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 7:18 AM UTC